Evonik on Friday raised its full-year guidance after price increases, stronger volumes and cost-cutting helped drive a better-than-expected second quarter. The German specialty-chemicals company now expects adjusted earnings before interest, taxes, depreciation and amortization for 2026 to range between €2.0 billion and €2.2 billion, up from the previous forecast of €1.7 billion to €2.0 billion. In 2025, Evonik posted adjusted EBITDA of about €1.9 billion.
The company said it expects second-quarter adjusted EBITDA between €600 million and €650 million, topping the €567 million average estimate from analysts polled by Vara Research. In the year-earlier period, Evonik reported adjusted EBITDA of €509 million.
Evonik also backed its cash conversion rate target of about 40% for the full year, above the 37% rate it achieved in 2025.
Free cash flow in the second quarter is expected to be higher than in the prior year, when the company recorded a loss of €211 million, Evonik said.
The advanced technologies segment has benefited from supply-chain disruptions that have hit competitors in Asia, the company said. However, as global marine shipping conditions normalize, that positive effect is expected to diminish later in the year, Evonik said.
“As a result, uncertainties persist for the second half of the year,” the company said.